Drug Profile
Research programme: cancer therapy adjuvants - VG Life Sciences
Alternative Names: 2-deoxyglucose/etomoxir - MetaCytoLytics; Dichloroacetic acid - MetaCytoLytics; MDT compounds - MetaCytoLyticsLatest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator University of Colorado Foundation; University of Vermont
- Developer VG Life Sciences
- Class Acetates; Antineoplastics; Deoxy sugars; Epoxy compounds
- Mechanism of Action Antimetabolites; Carnitine O-palmitoyltransferase inhibitors; Enzyme inhibitors; Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Feb 2023 Discontinued - Preclinical for Solid tumours (Late-stage disease, Adjuvant therapy) in USA (unspecified route)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours(Late-stage disease, Adjuvant therapy) in USA
- 30 Nov 2012 Viral Genetics is now called VG Life Sciences